RMD – Morgans rates the stock as Add

By Broker News | More Articles by Broker News

Results were broadly in line with Morgans estimates. Reimbursement changes across several countries have helped to increase the adaptation of cloud-based devices and this, in turn, has supported market share gains for ResMed.

The broker believes a growing installed base of connected devices and focus on resupply should bode well for continued strength in the high-margin mask/accessories category. Morgans maintains an Add rating and raises the target to $16.41 from $14.36.

Sector: Health Care Equipment & Services.

Target price is $16.41.Current Price is $14.22. Difference: $2.19 – (brackets indicate current price is over target). If RMD meets the Morgans target it will return approximately 13% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →